Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
JAMA Dermatology|December 11, 2024
Improving Diversity in a Novel Psoriasis Study: VISIBLE as a Framework for Clinical Trial Quality ImprovementAndrew Alexis, Amy McMichael, Neelam Vashi, et al.
The British Journal of Dermatology|August 28, 2025
SPECTREM Phase 3b Clinical Trial Results Through Week 16: Guselkumab Efficacy and Safety for the Treatment of Low Body Surface Area, Moderate Psoriasis With High-Impact Site InvolvementLinda Stein Gold, Alice B Gottlieb, April W Armstrong, et al.
The Lancet. Gastroenterology & Hepatology|December 17, 2023
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trialSilvio Danese, Remo Panaccione, Brian G Feagan, et al.
Gastroenterology|February 8, 2022
Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 StudyWilliam J Sandborn, Geert R D'Haens, Walter Reinisch, et al.
JAMA Dermatology|June 25, 2025
Guselkumab for Moderate to Severe Psoriasis Across All Skin Tones: Cohort A of the VISIBLE Randomized Clinical TrialAndrew Alexis, Amy McMichael, Jennifer Soung, et al.
JAMA Dermatology|June 25, 2025
Guselkumab for Moderate to Severe Scalp Psoriasis Across All Skin Tones: Cohort B of the VISIBLE Randomized Clinical TrialAmy McMichael, Mona Shahriari, Linda Stein Gold, et al.
Pageof 4